CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its lead drug for two types of liver diseases after observing “atypical” findings in one of the trials, sending its shares down 79% in premarket trading. The atypical findings in non-alcoholic steatohepatitis (NASH) were observed in patients who had shown an improvement in their condition during the trial, or had shown signs of disease stabilization, it added. The second trial was testing the drug in patients with primary sclerosing cholangitis, a chronic disease that damages the bile ducts. …read more
Source:: Yahoo Finance
